III期-话题@MedSci

#III期#

681篇内容 | 2790人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594587, encodeId=5117159458e34, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功, objectType=article, longId=164909, objectId=f4ff16490983, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4ff16490983, replyNumber=0, likeNumber=24, createdTime=2019-04-25, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4ff16490983, moduleTitle=礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4ff16490983)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594586, encodeId=60b2159458643, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=III期临床结果证实AveXis的基因疗法Zolgensma对I型脊髓性肌萎缩症的有效性, objectType=article, longId=164499, objectId=73ff16449919, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73ff16449919, replyNumber=0, likeNumber=21, createdTime=2019-04-19, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73ff16449919, moduleTitle=III期临床结果证实AveXis的基因疗法Zolgensma对I型脊髓性肌萎缩症的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73ff16449919)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594585, encodeId=7f17159458570, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险, objectType=article, longId=164340, objectId=bc7c1643405d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc7c1643405d, replyNumber=0, likeNumber=23, createdTime=2019-04-17, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc7c1643405d, moduleTitle=III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc7c1643405d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594584, encodeId=3a6e159458437, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=2019年美国临床内分泌学家协会（AACE）大会：Teprotumumab治疗甲状腺眼病的III期试验结果, objectType=article, longId=164221, objectId=3dc6164221e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dc6164221e6, replyNumber=0, likeNumber=81, createdTime=2019-04-15, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dc6164221e6, moduleTitle=2019年美国临床内分泌学家协会（AACE）大会：Teprotumumab治疗甲状腺眼病的III期试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dc6164221e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594583, encodeId=449a159458379, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Mallinckrodt完成了StrataGraft再生皮肤组织的III期临床试验的全面注册, objectType=article, longId=164219, objectId=e04a16421946, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e04a16421946, replyNumber=0, likeNumber=25, createdTime=2019-04-15, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e04a16421946, moduleTitle=Mallinckrodt完成了StrataGraft再生皮肤组织的III期临床试验的全面注册, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e04a16421946)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594582, encodeId=345015945825d, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验, objectType=article, longId=163509, objectId=ad4a1635092f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad4a1635092f, replyNumber=0, likeNumber=100, createdTime=2019-04-04, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad4a1635092f, moduleTitle=和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad4a1635092f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594581, encodeId=212815945813a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=JCO：恶性胸膜间皮瘤患者预防性照射：开放标签，多中心，III期随机临床试验, objectType=article, longId=163282, objectId=405216328246, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=405216328246, replyNumber=0, likeNumber=73, createdTime=2019-04-01, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=405216328246, moduleTitle=JCO：恶性胸膜间皮瘤患者预防性照射：开放标签，多中心，III期随机临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=405216328246)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594580, encodeId=f89d1594580eb, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=肿瘤电场疗法治疗复发性卵巢癌的III期关键性试验现已开展, objectType=article, longId=162856, objectId=38df16285682, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38df16285682, replyNumber=0, likeNumber=66, createdTime=2019-03-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38df16285682, moduleTitle=肿瘤电场疗法治疗复发性卵巢癌的III期关键性试验现已开展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38df16285682)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594579, encodeId=eaf815945e9cc, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Trizell制药宣布进行干扰素α-2b基因疗法治疗恶性胸膜间皮瘤的III期关键研究, objectType=article, longId=162736, objectId=45bb162e3664, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45bb162e3664, replyNumber=0, likeNumber=59, createdTime=2019-03-23, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45bb162e3664, moduleTitle=Trizell制药宣布进行干扰素α-2b基因疗法治疗恶性胸膜间皮瘤的III期关键研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45bb162e3664)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594578, encodeId=581015945e878, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Leber遗传性视神经病变的治疗或许不再是难题：GS010的REVERSE III期试验数据即将公布, objectType=article, longId=162523, objectId=00a21625233c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00a21625233c, replyNumber=0, likeNumber=40, createdTime=2019-03-19, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00a21625233c, moduleTitle=Leber遗传性视神经病变的治疗或许不再是难题：GS010的REVERSE III期试验数据即将公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00a21625233c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594577, encodeId=5dac15945e713, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=抗抑郁新药rapastinel遭遇挫折：未达到III期研究的主要终点, objectType=article, longId=161873, objectId=c2ee1618e324, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2ee1618e324, replyNumber=0, likeNumber=61, createdTime=2019-03-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2ee1618e324, moduleTitle=抗抑郁新药rapastinel遭遇挫折：未达到III期研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2ee1618e324)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594576, encodeId=6ad115945e660, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Vertex的VX-445三联组合方案治疗囊性纤维化的III期研究达到主要终点, objectType=article, longId=161868, objectId=3a6b1618681b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a6b1618681b, replyNumber=0, likeNumber=59, createdTime=2019-03-09, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a6b1618681b, moduleTitle=Vertex的VX-445三联组合方案治疗囊性纤维化的III期研究达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a6b1618681b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594575, encodeId=1f9a15945e53e, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=JCO：PROSTVAC在转移性去势抵抗性前列腺癌中的III期试验, objectType=article, longId=161545, objectId=3b1a161545a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b1a161545a9, replyNumber=0, likeNumber=63, createdTime=2019-03-04, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b1a161545a9, moduleTitle=JCO：PROSTVAC在转移性去势抵抗性前列腺癌中的III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b1a161545a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594574, encodeId=dbff15945e446, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=ImmunoGen的抗体 - 药物偶联物Mirvetuximab soravtansine未达到III期卵巢癌研究的主要终点, objectType=article, longId=161544, objectId=4fbf1615443f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4fbf1615443f, replyNumber=0, likeNumber=71, createdTime=2019-03-04, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4fbf1615443f, moduleTitle=ImmunoGen的抗体 - 药物偶联物Mirvetuximab soravtansine未达到III期卵巢癌研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4fbf1615443f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594573, encodeId=ac7715945e344, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=诺华的呼吸道合胞病毒疫苗ResVax在III期临床研究中失败, objectType=article, longId=161507, objectId=c9f516150e26, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9f516150e26, replyNumber=0, likeNumber=75, createdTime=2019-03-03, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9f516150e26, moduleTitle=诺华的呼吸道合胞病毒疫苗ResVax在III期临床研究中失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9f516150e26)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594572, encodeId=501015945e241, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Horizon的teprotumumab治疗活动性甲状腺眼病III期临床试验大获成功, objectType=article, longId=161504, objectId=8f841615044d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f841615044d, replyNumber=0, likeNumber=26, createdTime=2019-03-03, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f841615044d, moduleTitle=Horizon的teprotumumab治疗活动性甲状腺眼病III期临床试验大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f841615044d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594571, encodeId=323515945e147, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 , objectType=article, longId=161247, objectId=7cfc16124ea4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cfc16124ea4, replyNumber=0, likeNumber=41, createdTime=2019-02-28, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cfc16124ea4, moduleTitle=赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cfc16124ea4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594570, encodeId=48f815945e0c2, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=胰腺癌治疗Lynparza在胰腺癌III期研究中达到了主要目标 , objectType=article, longId=161221, objectId=c211161221c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c211161221c7, replyNumber=0, likeNumber=79, createdTime=2019-02-28, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c211161221c7, moduleTitle=胰腺癌治疗Lynparza在胰腺癌III期研究中达到了主要目标 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c211161221c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594569, encodeId=294d1594569f5, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=双重抗血小板疗法(替格瑞洛联合阿司匹林)在控制不良心血管事件的III期临床试验中大获成功, objectType=article, longId=161192, objectId=ee9f16119219, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee9f16119219, replyNumber=0, likeNumber=85, createdTime=2019-02-28, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee9f16119219, moduleTitle=双重抗血小板疗法(替格瑞洛联合阿司匹林)在控制不良心血管事件的III期临床试验中大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee9f16119219)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594568, encodeId=e17515945688c, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Ocaliva符合NASH引起的肝纤维化患者III期试验的主要目标, objectType=article, longId=160890, objectId=1e4416089059, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e4416089059, replyNumber=0, likeNumber=80, createdTime=2019-02-25, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e4416089059, moduleTitle=Ocaliva符合NASH引起的肝纤维化患者III期试验的主要目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e4416089059)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功

2019-04-25

智智灵药 (审核中...)

前往app查看评论内容

#III期#

III期临床结果证实AveXis的基因疗法Zolgensma对I型脊髓性肌萎缩症的有效性

2019-04-19

智智灵药 (审核中...)

前往app查看评论内容

#III期#

III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险

2019-04-17

智智灵药 (审核中...)

前往app查看评论内容

#III期#

2019年美国临床内分泌学家协会（AACE）大会：Teprotumumab治疗甲状腺眼病的III期试验结果

2019-04-15

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Mallinckrodt完成了StrataGraft再生皮肤组织的III期临床试验的全面注册

2019-04-15

智智灵药 (审核中...)

前往app查看评论内容

#III期#

和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验

2019-04-04

智智灵药 (审核中...)

前往app查看评论内容

#III期#

JCO：恶性胸膜间皮瘤患者预防性照射：开放标签，多中心，III期随机临床试验

2019-04-01

智智灵药 (审核中...)

前往app查看评论内容

#III期#

肿瘤电场疗法治疗复发性卵巢癌的III期关键性试验现已开展

2019-03-26

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Trizell制药宣布进行干扰素α-2b基因疗法治疗恶性胸膜间皮瘤的III期关键研究

2019-03-23

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Leber遗传性视神经病变的治疗或许不再是难题：GS010的REVERSE III期试验数据即将公布

2019-03-19

智智灵药 (审核中...)

前往app查看评论内容

#III期#

抗抑郁新药rapastinel遭遇挫折：未达到III期研究的主要终点

2019-03-09

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Vertex的VX-445三联组合方案治疗囊性纤维化的III期研究达到主要终点

2019-03-09

智智灵药 (审核中...)

前往app查看评论内容

#III期#

JCO：PROSTVAC在转移性去势抵抗性前列腺癌中的III期试验

2019-03-04

智智灵药 (审核中...)

前往app查看评论内容

#III期#

ImmunoGen的抗体 - 药物偶联物Mirvetuximab soravtansine未达到III期卵巢癌研究的主要终点

2019-03-04

智智灵药 (审核中...)

前往app查看评论内容

#III期#

诺华的呼吸道合胞病毒疫苗ResVax在III期临床研究中失败

2019-03-03

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Horizon的teprotumumab治疗活动性甲状腺眼病III期临床试验大获成功

2019-03-03

智智灵药 (审核中...)

前往app查看评论内容

#III期#

赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 

2019-02-28

智智灵药 (审核中...)

前往app查看评论内容

#III期#

胰腺癌治疗Lynparza在胰腺癌III期研究中达到了主要目标 

2019-02-28

智智灵药 (审核中...)

前往app查看评论内容

#III期#

双重抗血小板疗法(替格瑞洛联合阿司匹林)在控制不良心血管事件的III期临床试验中大获成功

2019-02-28

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Ocaliva符合NASH引起的肝纤维化患者III期试验的主要目标

2019-02-25

科室
- - 订阅+
  - 更多科室
工具
服务